COVID-19 and Fatty Liver Disorders

Area of Science:

• Hepatology
• Infectious Diseases
• Metabolic Disorders

Background:

• The COVID-19 pandemic caused widespread illness, particularly affecting individuals with metabolic conditions like obesity, diabetes, and liver disease.
• Non-alcoholic fatty liver disease (NAFLD) is a prevalent cause of chronic liver disease (CLD), creating a significant overlap with COVID-19 patient populations.

Purpose of the Study:

• To analyze the relationship between COVID-19 and fatty liver disorders (FLD).
• To identify molecular mechanisms and clinical predictors of severe COVID-19 in FLD patients.
• To examine changes in FLD management during pandemics, emphasizing telemedicine and preventative interventions.

Main Methods:

• Literature review focusing on molecular mechanisms, clinical presentations, and management strategies.
• Analysis of the interplay between SARS-CoV-2 infection and the spectrum of fatty liver disease.
• Exploration of telemedicine's role in managing FLD during health crises.

Main Results:

• Metabolic comorbidities, including FLD, are associated with increased COVID-19 severity.
• Specific molecular pathways link SARS-CoV-2 infection to liver damage and metabolic dysfunction.
• Telemedicine has emerged as a crucial tool for managing FLD patients during the pandemic.

Conclusions:

• FLD patients face heightened risks during COVID-19, necessitating tailored management strategies.
• Understanding the molecular basis of COVID-19's impact on the liver is crucial for developing effective treatments.
• Adapting healthcare delivery, such as through telemedicine, is vital for supporting vulnerable patient groups during pandemics.